DLB patients also more often had several co-occurring SDs. The presence of any SD was associated with more neuropsychiatric symptoms, higher morbidity, more parkinsonian symptoms and excessive daytime sleepiness. Antiparkinsonian medication was used more often in RBD, restless leg syndrome (RLS) and periodic limb movements, and benzodiazepines were also common in RLS. Conclusions: Sleep problems are more common in DLB patients compared to AD, and are associated with more clinical impairment. DLB patients frequently have several sleep problems occurring simultaneously, which suggests a need for screening and accurate assessment of sleep in DLB.
Introduction
Sleep disturbances (SDs) are common in patients with all forms of dementia (reported as between 28 [1] and 73% [2] ) and have so far been best described in Alzheimer's disease (AD). They encompass sleep disorders such as sleep-disordered breathing (SDB) [3] , insomnia [4] and desynchronization of the chronobiological sleep cycle [5, 6] , as well as behaviours disrupting nocturnal sleep, such as agitation, physical aggression, loud vocalizations and wandering [7] .
However, sleep disorders have also been observed in patients with other forms of dementia and the prevalence of SDs is even higher in dementia with Parkinson's disease (PD) and dementia with Lewy bodies (DLB) [8, 9] . So far, there have only been a few studies that systematically compare SDs in AD and DLB [10] [11] [12] [13] . The main differences found are an increased severity of SD and a higher frequency of REM sleep behaviour disorder (RBD) and other nocturnal problems, such as restless leg syndrome (RLS), periodic limb movements (PLMS) and sleepwalking (SW), in DLB. The true prevalence and implications of RBD in DLB are not well established and studies report frequencies ranging from 40 [9] to 75.5% [14] .
Research on RBD in various forms of dementia has confirmed a frequent co-occurrence and an association with Lewy bodies (LB) present in the brain stem, which are alpha-synuclein positive. The association of RBD with PD, DLB, multiple system atrophy and other diseases with pathological LB is now well established [15] . The importance of RBD in the diagnosis of DLB has been recognized, which is reflected in the revised diagnostic consensus criteria [16] .
Little is known about the presence of other sleep-related disorders (RLS, PMLS, SW, SDB) in patients with dementia. The frequency of RLS increases with age and affects approximately 19% over the age of 80 years [17] . PLMS may be present in 34% of patients with AD compared with 3.9% of the healthy population [18] . Both disorders are also more frequent in patients with RBD and often coexist with each other [19] . In turn, the presence of SDB in dementia is estimated to be approximately 50% [20] and increases with age and the severity of dementia. It is not entirely clear whether a high prevalence and cooccurrence of SD in dementia is accidental or linked to specific and common anatomical and pathophysiological disturbances. Greater knowledge about the frequency of these syndromes in dementia and consideration of other factors, such as biomarkers and clinical features, could help in understanding the pathophysiology of some aspects of the degenerative processes.
We hypothesised that the complexity of SDs is much greater in DLB than previously reported, and that the presence of RBD is associated with poorer cognitive functioning and more anxiety, depression, fluctuations, hallucinations and excessive daytime sleepiness (EDS). Therefore, the aims of the current study were: (1) to examine the frequency of SDs such as insomnia, RBD, PLMS, sleep-related leg cramps (SRLC), SW, SDB, RLS and EDS in patients with DLB compared to patients with AD; (2) to investigate possible differences in sleep disorders in patients with DLB versus patients with AD with regard to clinical variables, such as the severity of dementia, fluctuations, anxiety, depression and medications, and (3) to investigate the association between RBD, RLS and PLMS and medication use.
Materials and Methods

Selection of Subjects
Patients with probable or possible DLB or AD were selected from the Dementia Study of Western Norway (DemVest) [21] , which included all patients with a first time clinical diagnosis of mild dementia (Mini-Mental State Examination, MMSE >20) and Clinical Dementia Rating (CDR) global score ≤ 1 [21] . In order to achieve a larger sample with DLB patients, additional patients with an MMSE score of 16 or higher were recruited from clinics for old age psychiatry from 2010 until the end of 2013.
Patients were assessed with a structured interview and a general medical examination including blood samples. 123 I-FP-CIT-SPECT was performed in a subgroup comprising patients with suspected DLB. MRI or CT was performed in order to exclude other conditions that could influence cognition. Patients were also assessed with a comprehensive neuropsychological test battery and the motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). The details of subject selection and testing have been described previously [21] .
Dementia Diagnosis
Participants were diagnosed with dementia according to the DSM-IV. Patients were classified as having AD when fulfilling the criteria of the National Institute and Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders (NINDS-ADRDA). Diagnosis of DLB was made in accordance with the Third Report of the DLB Consortium, entitled 'Diagnosis and management of dementia with Lewy bodies'. Clinical diagnoses were evaluated every second year and after 5 years of annual follow-up by a consensus panel of dementia experts, which re-evaluated the clinical diagnoses based on all available information.
Sleep Assessment
Insomnia was assessed with item 11 from the Neuropsychiatric Inventory 12 (NPI), using caregivers as informants. Symptoms were assessed for the last 30 days, rating both frequency (1-4) and severity (1-3), which were multiplied into a symptom domain score (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . A score of 4 or higher was considered as clinically significant insomnia [22] .
The probable presence of parasomnias such as RBD, PLMS, SRLC, SW and RLS were assessed with the Mayo Sleep Questionnaire (MSQ) [23] . The MSQ is a 16-item questionnaire specifically designed to detect RBD, using bed-partners as informants. Patients received a probable RBD diagnosis when the core question: 'Have you ever seen the patients appear to act out his/her dreams while sleeping? (punched or flailed arms in the air, shout-
Other Assessments
The MMSE is a brief test used for screening for cognitive impairment and it was used for enrolling patients into the study. The CDR global score was used for assessing the severity of dementia (range 0-3). The rating scale comprises six cognitive and practical domains: memory; orientation; judgement and problem-solving; community affairs; home and hobbies, and personal care.
Neuropsychiatric symptoms, such as anxiety, depression, delusions and hallucinations, were evaluated with the NPI (12 items, range 0-144), based on caregiver reports. Fluctuations in cognition were rated using the Clinician Assessment of Cognitive Fluctuations (range 0-12) and Mayo Fluctuation Scale (range 0-4). Details for evaluating the presence of fluctuations are described elsewhere [2] . A subject's general health status was assessed with the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) by a physician (range 0-56, higher scores indicating severe comorbidity).
Data about medications that may affect sleep (benzodiazepines, antiparkinsonian drugs, atypical hypnotics, neuroleptics, antidepressants, antiepileptics and opioids, β-blockers), routine blood samples and medical histories were taken from the clinical record file and supplemented from medical documentation.
Statistical Analyses
The statistical analyses were conducted with SPSS (version 21.0.0; SPSS Inc., Chicago, Ill., USA), and a p value <0.05 was considered as statistically significant. Simple descriptive analyses were used to summarize demographical data. Differences in demographic, neuropsychiatric symptoms and medication were analysed with Pearson's χ 2 test for normally distributed data, and with the Mann-Whitney U test or Fisher's exact test for non-normally distributed data. Differences in the frequency of sleep problems were analysed with Pearson's χ 2 test and the results are presented as odds ratios (ORs) with 95% confidence intervals (CIs).
Ethics
The Regional Committees for Medical and Health Research Ethics (REK) and the Norwegian Social Science Data Services (NSD) approved the study. The study was performed according to the Declaration of Helsinki. The patients provided written informed consent to participate in the study after the study procedures had been explained in detail to the patient and a caregiver.
Results
Demographic and Clinical Characteristics
The study sample comprised 221 age-matched patients with dementia, 138 (62.4%) with AD and 83 (37.6%) with DLB. There were more men in the DLB group compared to the AD group (50.6 vs. 30.4%, p = 0.003). Patients with DLB had lower mean MMSE scores and higher NPI total and CIRS scores. Table 1 displays the demographic and clinical characteristics of the study groups.
Frequency of SDs
In all, 123 (55.7%) subjects with dementia suffered from at least one SD. SDs were significantly more frequent in patients with DLB than in AD (any sleep disorder: 73.2 vs. 45.7%, OR 3.2, 95% CI 1.8-5.9, p < 0.001). Three or more SDs were present more often in subjects with DLB than those with AD (37.8 vs. 9.4%, OR 5.8, 95% CI 2.8-12.1, p < 0.001; table 2 ).
Insomnia
Insomnia was present in 77 (34.8%) of all 211 cases, with a significantly higher frequency among DLB patients than in AD (p < 0.001).
RBD
Thirty-four patients (20.7%) had probable RBD, 9 of them in the AD group (8.8%) and 25 in the DLB group (40.3%, p < 0.001). The average duration of RBD symptoms in AD was 4.6 years (SD = 4.0) compared with 6.2 years (SD = 7.7) in DLB (p = 0.583). Two DLB patients and 3 bed partners were seriously injured during RBD episodes, while no serious injuries were reported in the 
Other Sleep Disorders and EDS
The frequency of all other sleep disorders, such as PLMS, RLS, SRLC, SW and SDB, was significantly higher in the DLB group than in the AD subjects. EDS was significantly more frequent in the DLB group than in AD patients (40.7 vs. 18.3%, p = 0.002).
SD Correlates
When comparing the patients with at least one SD a male predominance was observed (p = 0.009). Furthermore, higher total NPI (p = 0.028), especially in the delusions domain (p = 0.041), higher CIRS-G (p = 0.019), higher UPDRS (p < 0.001) and higher ESS (p = 0.022) and fluctuations were evident in the DLB group. The presence of RBD was associated with a higher total NPI in particular (p = 0.028). There were no significant associations between the presence of any sleep disorder or RBD and 
Associations between Medications and RBD, RLS and PLMS
At least one medicine was taken by 210 (95%) participants, while 9 (4.3%) used 10 or more (total range 0-13). The mean number of medication was 4.3 and did not differ between the AD and DLB groups. Dementia medication was used by 98 (46%) subjects, divided equally between both groups (47.4% AD vs. 43.3% DLB, p = 572). Benzodiazepines, neuroleptics and antiparkinsonian medications were used more frequently in the DLB group. There were no other significant differences in medication between the groups ( table 4 ) .
Pharmacological treatment was not associated with the frequency of RBD, RLS or PLMS in general. Only antiparkinsonian medication was used more often in the RBD, RLS and PLMS groups than in patients without these sleep disorders, and benzodiazepines in those affected by RLS ( table 5 ).
Discussion
Our results suggest that more than half of the caregivers and/or patients reported at least one problem with nocturnal sleep in AD and DLB, with a predominance of insomnia. Sleep problems were more common in DLB compared to AD patients, with more complex SD profiles and several problems occurring simultaneously. This is consistent with previous studies [10, 11, 13] . A significantly larger group of patients with DLB had three or more SDs in comparison with the AD subjects. This can be partly explained by the fact that subjects with DLB had more medical comorbidities. They also had slightly lower MMSE scores than the AD group, but the clinical importance of the difference could be dubious (mean 23.8 vs. 23.0), especially since the groups had equal CDR scores. A higher total NPI score in DLB patients could also influence the severity of SD, although sleep pathology itself is an independent risk factor for the presence and severity of neuropsychiatric symptoms [24] . However, the most probable explanation is differences between DLB and AD at the neuropathophysiological level. The percentage of sleep disorders in our study is comparable with other reports [11] , but studies published so far have reported large variations in the prevalence of sleep disorders, i.e. from 25 [4] to 60% [12] , in all types of dementia.
The most distinctive sleep disorder among patients with DLB is RBD, which is correlated with alpha-synuclein pathology. The relationship has been confirmed in many studies, including neuropathologically [25, 26] . This is why RBD is now considered a potential early marker of neurodegenerative disease development associated with alpha-synuclein pathology [27, 28] . So far it is not clear why alpha-synuclein specifically destroys structures involved in sleep regulation, especially in centres controlling REM sleep atonia (REM-on and REM-off centres: proposed REM-off regions include the ventrolateral part of the periaqueductal grey matter and lateral pontine tegmentum; REM-on regions include the precoeruleus and sublaterodorsal nucleus) [15] . Whether it depends only on deposit localisation predominantly in the pontomedullary brainstem or there are also influences on other neurobiochemical aspects of sleep is yet to be clarified. It is postulated that more serious SD in DLB than in AD is due to more diffuse and primary damage of the basal ganglia and cholinergic tracts, both cortical and subcortical, and the presence of synuclein deposits in strategic locations for sleep control in the brain [29] .
In addition to a higher prevalence of RBD, our results also indicate increased odds for other SDs, such as insom- 4 Zopiclone, zolpidem, clomethiazole. 5 Typical: haloperidol, levomepromazine, prochlorperazine, perfenazine; atypical: clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole.
6 Donepezil, rivastigmine, memantine. 7 Tricyclic antidepressants, citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, mirtazapine, mianserin, duloxetine, reboxetine. 8 Valproate acid. 9 Codeine, oxycodone, fentanyl, buprenorphine. 10 nia, RLS, PLMS, SW, SDB and EDS, in DLB. Although this may be coincidental, it is also possible that RBD is associated with other disorders, such as RLS, PLMS and EDS. It is known that patients with RBD/REM sleep without atonia (RSWA) often have many motor symptoms during sleep [23] . However, the high frequency of sleep disorders involving motor symptoms may not be solely explained by the lack of muscle atonia during REM sleep. It has been postulated that the high occurrence of PLMS in RBD, especially during REM sleep, might be triggered by the lack of muscle atonia and absence of brainstem inhibition on spinal motor neurons, which is one of the main features of RBD [19] . However, PLMS and SW are typically associated with the phases of non-REM sleep whilst RLS is not connected to sleep, which raises the possibility that PLMS in RBD have different causes. It has been shown that PLMS in patients with RBD occur equally both in non-REM sleep and REM sleep, which is not typical in idiopathic PLMS [19] . In one study of PLMS in RBD, Fantini et al. [30] showed that PLMS are probably more frequent in REM sleep in RBD/RSWA, and were not improved by pramipexole (a dopamine agonist). At the same time, PLMS is extremely prevalent in RLS [31] , and our study also reflects this trend since 75% of our patients with RLS also have PLMS. Although RLS is probably associated with iron-dopamine connections [32, 33] , and the coexistence of RLS and RBD could suggest dopamine transmission pathology, it is increasingly evident that RBD is not only the result of damage to the dopaminergic system. There is now significant evidence that the serotonergic and cholinergic systems could also be strongly involved based on observations that some medications (especially stimulating the serotonergic system or blocking acetylcholine transmission) can induce RBD [34] .
In our study, 31.6% of the DLB patients suffered from RLS. The occurrence of RLS in DLB has not been a subject of much research. The frequency may, however, be comparable to that in PD, with estimates at 0-20.8% [35, 36] . When it comes to PD, it has been suggested that there is a need for a better characterization of the spectrum of motor restlessness [37] , which may also be the case for DLB. SW is also a rarely described disorder in DLB, but several studies have shown the possibility of a higher incidence of SW in PD, also in correlation with RBD (parasomnia overlap syndrome) [38, 39] . Regarding SRLC in DLB, we did not find research reporting its frequency, but in our material the percentage was as high as 36.2%.
It is obvious that complex sleep problems significantly impair the clinical status and functioning of patients. In our study, the group with at least one sleep disorder had more neuropsychiatric symptoms, higher comorbidity and more expressed parkinsonian symptoms, as well as a higher frequency of fluctuations, hallucinations and more serious daytime sleepiness. It is impossible to conclude from our data if morbidity is the cause of sleep problems or the consequence, but associations seem to be bidirectional. A similar association has been observed between the severity of motor parkinsonian symptoms, which contribute to SD, and SD can also worsen motor symptoms. In our study, there were not, however, significant associations between SD and depression, anxiety or cognitive status (CDR, MMSE). Patients with RBD showed a higher score only on the NPI total, and not in EDS or fluctuations. Several other studies have reported that RBD patients are predisposed to hallucinations [40] or that RBD increases the risk for hallucinations [41] , but in our sample this trend was not observed. In accordance with other studies, which reported results from baseline, we could not show that RBD was correlated with more impaired cognition (MMSE), although the previous studies were carried out on subjects with RBD who developed cognitive symptoms in the follow-up period and not at baseline [40, 42, 43] . The evidence for the association between RBD and EDS is not conclusive. Some authors report that RBD impacts EDS [42, 44] , whereas others have not found such correlations [45] . However, these studies have been conducted with patients with PD, and we could not find similar studies with DLB.
A large number of our patients received various cardiac drugs (many of which were β-blockers), antidepressants, hypnotics and other drugs affecting the central nervous system, but we did not notice significant influences on different SDs. Analyses of medications revealed that antiparkinsonian drugs and neuroleptics were used more often in patients with DLB, but this is probably due to symptomatic treatment of the parkinsonian and psychotic symptoms, respectively. The more common use of benzodiazepines in patients with DLB can be explained by higher rates of SD, and is probably also due to more frequent episodes of agitation and admissions to nursing homes, where the use of sedatives and neuroleptics is weakly controlled [46] . In a review study from 2010, Hoque and Chesson [47] analysed 32 articles on druginduced RLS, PLMS and RBD. They concluded that the strongest evidence for drug-induced RLS involved tricyclic antidepressants [48] and SSRIs (i.e. escitalopram, fluoxetine), mianserin, mirtazapine and some neuroleptics [47] . Other drugs with weaker associations were Lthyroxine, pergolide, L -dopa and tramadol. The strongest evidence for drug-induced PLMS was described for the SSRIs bupropione and venlafaxine. For RBD/RSWA it was shown that bisoprolol [49] , clomipramine, selegiline, phenelzine, mirtazapine, β-blockers and SSRIs have the potency to induce these SDs [49, 50] . Thus, it is important to account for medications that patients use in order to eliminate their potential effect on the induction of these parasomnias.
A strong aspect of our research is that the cohort was relatively large (especially the DLB group), and included all centres in West Norway specialized in dementia diagnosis. Some of the previously reported studies were small [11, 13] or with only a small number of DLB subjects [12] . The large study conducted by Bliwise et al. [10] collected data from 4,192 AD and 339 DLB patients, but was limited by the use of NPI-Q as the only sleep-assessment tool.
The clinical diagnoses were evaluated every second year and at the end of the 5-year follow-up by a panel of specialists, and were consequently corrected in relation to baseline diagnoses using the same, reliable instruments. A large number of patients underwent 123 I-FP-CIT SPECT, which could also increase the sensitivity and specificity of the diagnosis of DLB.
We assessed sleep disorders with a number of wellestablished scales and questionnaires. The MSQ was chosen as the best-validated anamnestic tool to assess the presence of RBD, which has a high sensitivity (96-100%) and specificity (74-95%) for an RBD diagnosis [23, 51] . The MSQ is also highly predictive in the assessment of SRLC and RLS [23] .
Moreover, analyses were carried out to exclude the presence of other medical conditions which could lead to secondary SDs. We analysed ferritin levels, electrolyte disturbances, renal parameters, excessive intake of alcohol, caffeine intake, smoking, polyneuropathy (anamnestic) and hyper-or hypothyroidism without finding any correlations between them and SD (data not shown).
There were also some limitations to our study. We assessed SDs based on interviews of the bed partner and did not verify the nocturnal disturbances with PSG (polysomnography), which is the gold standard for determining the presence of RBD and other sleep disorders. Although 90% of the informants were close spouses and bed partners, it is nevertheless possible that the informants may have over-or under-reported symptoms. It is well known that discrepancies between informants (patients, caregivers) exist. Patients with mild dementia and mild depression can in reality sleep better than their caregivers rapport [52] . Also PSG and actigraphy records confirm that subjects have a tendency to overestimate their sleep problems [53] .
The use of MSQ in the assessment of RBD could also overestimate the number of RBD cases because it is difficult to distinguish RBD from movement activity in SDB. On the other hand, MSQ could underestimate cases with RWSA. There are also some limitations concerning other questions in the MSQ, i.e. questions about PLMS, SW and SDB, as it may not predict the presence of these SDs accurately.
Another limitation was the lack of autopsy verifications of all clinical diagnoses. However, in the first 25 cases to come to autopsy, the clinical diagnoses were verified with pathological confirmation.
Our findings suggest that further studies are needed to achieve a better understanding of the relationship between SDs, cognition and fluctuations in DLB. Plenty of studies on RBD in PD have been conducted, but there is also a need for precise studies of RBD in DLB. Future studies in this field should focus on developing more accurate and easily available diagnostic tools, which could be of help in early neuroprotective interventions. Our data also indicate the importance of the accurate assessment of SDs in patients with dementia.
